ARCT Sep 2024 50.000 call
| Previous close | 2.6000 |
| Open | 2.6000 |
| Bid | 0.0000 |
| Ask | 1.7500 |
| Strike | 50.00 |
| Expiry date | 2024-09-20 |
| Day's range | 2.6000 - 2.6000 |
| Contract range | N/A |
| Volume | |
| Open interest | 31 |
GuruFocus.comInsider Sale: CFO Andy Sassine Sells 50,000 Shares of Arcturus Therapeutics Holdings Inc (ARCT)
On June 12, 2024, Andy Sassine, the Chief Financial Officer of Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT), executed a significant transaction by selling 50,000 shares of the company.
Business WireArcturus Therapeutics Presents New Clinical Data at 47th Annual European Cystic Fibrosis Conference
SAN DIEGO, June 07, 2024--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease vaccines and medicines to treat unmet medical needs within liver and respiratory rare diseases, today presented Phase 1 results in healthy volunteers and Phase 1b interim data in people with CF for ARCT-032, an inhaled investigational mRNA therapeutic, at the 47th European Cystic Fibrosis Conference in G
GuruFocus.comInsider Sale: Chief Scientific Officer & COO Pad Chivukula Sells 26,000 Shares of Arcturus ...
Chief Scientific Officer & Chief Operating Officer Pad Chivukula of Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT) sold 26,000 shares of the company on June 3, 2024, as reported in a recent SEC Filing.
